The benefit of conversion therapy for patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab using newly established oncological resectability criteria in Japan. - Shimose S; Saeki I; Ito T; Takeuchi Y; Tani J; Tomonari T; Sasaki R; Sasaki K; Kakizaki S; Hatanaka T; Iwamoto H; Tanabe N; et al. (Hepatology international, 2025)